Xolair

Lea en español

Xolair
Xolair (the trade name for Omalizumab), is a drug that has been approved to treat teenagers and adults with severe allergic asthma since its introduction in Australia in 2002. Approved by the U.S. Food and Drug Administration (FDA) in 2014, it has been held out as being particularly effective for people who cannot be treated with H1 antihistamines or do not benefit from high doses of corticosteroids. It has also been used to treat people who suffer chronically from hives.

A number of adverse side effects have been linked to the use of Xolair, including:

  • Anaphylactic shock or anaphylaxis (a life-threatening allergic reaction)
  • Increased risk of heart disease
  • Increased risk of stroke
  • Masking of warning signs of certain cancers

If you or someone you love has suffered injury after being prescribed Xolair, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

The 25th Amendment to the United States Constitution Is in the News

The Constitutional Process for Replacing a President Who Lacks Capacity to Serve The United States C…

15 Oct 2020, Thursday

The Legal Consequences of Voting Twice

Why You Shouldn’t Follow Trump’s Suggestion to “Test Integrity of Electoral System” | P…

21 Sep 2020, Monday

Medical Malpractice: How It Differs from Other Negligence Claims

The Standard of Care – What You Must Prove to Recover for Your Losses When you’re hurt in an…

21 Aug 2020, Friday